Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is a multinational healthcare company that specializes in personalized cancer diagnostics through their proprietary genomic and epigenetic technologies. Despite some setbacks with discontinued tests and lowered revenue estimates, the company's strategic acquisitions and expansion into high-growth areas show promise for future growth. Additionally, their strong performance in 2025 and continued confidence from management suggest that the company's fundamentals are solid, making it an attractive stock for investors.

Bears say

MDxHealth is heavily reliant on its urology-focused product portfolio and faces potential risks with the discontinuation of its UTI and Resolve tests, as well as potential reimbursement challenges for its GPS test. Additionally, the company's revenue growth and profit margins may be impacted by the integration of their recent ExoDx acquisition and the timing of contingent payments to Exact Sciences for the technology. These factors, combined with a potential double-digit revenue growth opportunity, create uncertainty for the company's financial performance, leading to a negative outlook.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of May 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.